Overview
Autoimmune sensory neuropathy, particularly sensory ganglionopathy, involves immune-mediated damage to sensory neurons or dorsal root ganglia, leading to sensory deficits and ataxia. 1Diagnosis
Clinical presentation includes progressive sensory loss and ataxia.
Nerve conduction studies often reveal abnormalities consistent with sensory neuron involvement.
Biopsy may confirm associated dermatological conditions like livedoid vasculopathy. 1Management
First-line treatments: Corticosteroids (e.g., prednisolone) and immunosuppressive agents (e.g., mycophenolate mofetil).
Adjunctive treatments: Rituximab may stabilize symptoms and nerve conduction abnormalities when first-line therapies fail. 1Special Populations
No specific data provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts. 1Key Recommendations
Initiate treatment with corticosteroids and mycophenolate mofetil for autoimmune sensory ganglionopathy. (Evidence: Moderate 1)
Consider adding rituximab if there is no response to initial immunosuppressive therapy, as it may stabilize symptoms and nerve function. (Evidence: Weak 1)
Regular nerve conduction assessments are essential for monitoring disease progression and treatment efficacy. (Evidence: Expert opinion 1)References
1 Alix JJ, Hadjivassiliou M, Ali R, Slater D, Messenger AG, Rao DG. Sensory ganglionopathy with livedoid vasculopathy controlled by immunotherapy. Muscle & nerve 2015. link